This document provides Harvard Pilgrim Health Care prior authorization medical necessity criteria for a broad set of pharmacy and specialty drug products. It defines product-specific coverage conditions, required clinical documentation, prescriber restrictions, prerequisite therapy or Part D prerequisites where applicable, and typical coverage durations used to adjudicate requests for authorization. Examples of drug-specific requirements include diagnosis confirmation, mutation or biomarker test results, prior trial/failure or intolerance to specified therapies, and site-of-care or usage details needed to determine Medicare Part B versus Part D coverage.
The scope of products covered ranges across oncology, immunology/biologics, pulmonary hypertension, cystic fibrosis, infectious disease, neurology, hematology, and other specialty categories. For many entries the policy specifies that the prescribing clinician should be a relevant specialist (for example, oncologist, rheumatologist, pulmonologist, neurologist, or allergist) and notes typical authorization periods (commonly 2 years, with specific exceptions such as certain agents having 1-year initial coverage).
The policy framework requires submission of the required medical information listed for each product (for example: documented diagnosis, relevant genetic or laboratory testing, documentation of prior therapies and responses, and monitoring plans for agents with safety lab requirements). Requests missing required diagnostic confirmation, prior-therapy documentation, or information about the drug use/setting (when needed to determine Part B vs Part D) may be denied or returned for clarification.
Providers should consult the product-specific criteria in this section when preparing prior authorization requests so that the submitted documentation demonstrates that all of the listed medical necessity conditions for the requested indication are satisfied. Where indicated, step-therapy or prerequisite Part D drug requirements, explicit exclusions (for example, non‑approved uses), and reauthorization/continuation criteria (including demonstration of clinical response) are specified and must be met for approval.